Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced ...
In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric patients 12 ...
Synnovation will receive total cash consideration of up to $3 billion, consisting of $2 billion in upfront cash and up to $1 ...
Survey of 800+ HCPs Finds Menopause Care is the #1 Area Where Providers Expect the Greatest Improvement in the Next 5 ...
A Comprehensive Guide to the Fetal Bovine Serum MarketThe biotechnology and pharmaceutical industries are currently ...
The medical landscape undergoes a rapid transformation as precision becomes the standard of care. At the heart of this ...
Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive ...
The Assistive Technology Market refers to the global industry focused on designing, manufacturing, and distributing devices, ...
New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various ...
A SmartSense survey of 150 U.S.-based hospital CFOs finds 94% of respondents reporting unexpected expenses related to ...
OverviewThe Global Medical Holographic Imaging Market is valued at USD 2.2 Billion in 2024 and is projected to reach a value ...
Rossi Brings Decades of Leadership as Convergent Advances its Alpha-based Radioantibody for Prostate Cancer to Late-Stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results